- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07937891
The PRECISE-DIET Trial
Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial
People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.
A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.
The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zandra Overgaard Pedersen, MSc. Health Science
- Phone Number: 24456114
- Email: zandra.overgaard.pedersen@regionh.dk
Study Contact Backup
- Name: Bettina Ewers, PhD
- Phone Number: 30912997
- Email: bettina.ewers@regionh.dk
Study Locations
-
-
-
Herlev, Denmark, 2730
- Steno Diabetes Center Copenhagen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- T2D
- Diabetes duration of ≥12 months
- Age ≥18 years
- HbA1c ≥58 mmol/mol
- Attending the SDCC outpatient clinic
- Provided voluntary signed informed consent
Exclusion Criteria:
- Inability to understand the study information
- Medical complications that prevent lowering HbA1c to below 58 mmol/mol
- Use of insulin therapy
- Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
- Systematic use of corticosteroids
- Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
- Circumstances that affect HbA1c (e.g., liver disease and anaemia)
- Known or suspected drug or alcohol abuse
- Pregnancy or breastfeeding or plans of pregnancy within the study period
- Participation in other clinical trials
- Individuals with a BMI of <27 kg/m²
- Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Personalised dietary intervention
CGM-supported personalised carbohydrate recommendations |
Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes. |
|
Active Comparator: Standard dietary counselling
Standard dietary counselling for type 2 diabetes |
Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HbA1c
Time Frame: Baseline to 6 months
|
Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months |
Baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HbA1c at 12 months
Time Frame: Baseline to 12 weeks and 12 months
|
Between-group difference in HbA1c change (mmol/mol) |
Baseline to 12 weeks and 12 months
|
|
Time in range (TIR)
Time Frame: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose 3.9-10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time above range (TAR)
Time Frame: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose >10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time below range (TBR)
Time Frame: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose <3.9 mmol/L |
Baseline, 6 and 12 months
|
|
Estimated HbA1c
Time Frame: Baseline, 6 and 12 months
|
HbA1c estimated from CGM data (mmol/mol) |
Baseline, 6 and 12 months
|
|
Change in glycaemic variability
Time Frame: Baseline, 6 and 12 months
|
Coefficient of variation (%) derived from CGM |
Baseline, 6 and 12 months
|
|
Body mass index (BMI)
Time Frame: Baseline, 6 and 12 months
|
kg/m² |
Baseline, 6 and 12 months
|
|
Waist and hip circumference
Time Frame: Baseline, 6 and 12 months
|
cm |
Baseline, 6 and 12 months
|
|
Blood pressure
Time Frame: Baseline, 6 and 12 months
|
Systolic and diastolic (mmHg) |
Baseline, 6 and 12 months
|
|
plasma glucose
Time Frame: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Plasma insulin
Time Frame: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
C-peptide
Time Frame: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
Total cholesterol
Time Frame: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
LDL cholesterol
Time Frame: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
HDL cholesterol
Time Frame: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Triglycerides
Time Frame: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Diabetes distress (questionnaire)
Time Frame: Baseline, 6 and 12 months
|
Problem Areas in Diabetes (PAID) score |
Baseline, 6 and 12 months
|
|
Treatment satisfaction (questionnaire)
Time Frame: Baseline, 6 and 12 months
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score |
Baseline, 6 and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in glucose-lowering medication
Time Frame: Baseline, 6 and 12 months
|
Changes in type and dose of glucose-lowering medication |
Baseline, 6 and 12 months
|
|
Personality traits (questionnaire)
Time Frame: Baseline
|
Big Five Inventory (BFI-44) scores |
Baseline
|
|
Dietary intake
Time Frame: Baseline and 6 months
|
Total energy intake and macronutrient composition from a 3-day food record |
Baseline and 6 months
|
|
Physical activity
Time Frame: Baseline and 6 months
|
Physical activity level measured with an AX3 accelerometer worn for 7 days |
Baseline and 6 months
|
|
Carbohydrate estimation ability (questionnaire)
Time Frame: Baseline, 6 and 12 months
|
Accuracy of participants' carbohydrate estimates |
Baseline, 6 and 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-26063596
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.